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SUMMARY A case is presented of a female Caucasian patient with 
chronic peripheral blood eosinophilia and unusual skin manifestations. 
Within a couple of years, the patient developed multiple hyperkera-
totic and hyperpigmented papules and plaques all over the body, pal-
moplantar keratoderma, pachydermia of acral parts of the body, and 
generalized pruritus. Generalized lymphadenopathy appeared. Other 
relevant symptoms were persistent peripheral blood hypereosinophilia 
and increased level of total IgE. The patient was diagnosed with a very 
rare condition, pachydermatous eosinophilic dermatitis, and was ad-
ministered combined therapy with dapsone, oral methylprednisolone 
and fexophenadine. After one month of treatment, the skin changes 
markedly improved.
KEY woRDS: hypereosinophilia, hypereosinophilic syndrome, pachy-
dermia, treatment, hypereosinophilic dermatitis, eosinophilic dermatitis
IntRoDUCtIon
Hypereosinophilia is a frequent symptom that may 
occur in the course of many underlying diseases. The 
most common reasons are parasitoses and allergic re-
actions; however, some less frequently observed dis-
orders should also be taken into consideration on dif-
ferential diagnosis. The first description of a case with 
persistent eosinophilia with systemic involvement ap-
peared in 1919 (1). In 1968, the term “hypereosinophilic 
syndrome” (HES) was proposed for patients with chron-
ic peripheral hypereosinophilia and organ involvement 
related to eosinophilic infiltration (2). Seven years later, 
the following diagnostic criteria for idiopathic HES were 
established: peripheral eosinophilia of unknown origin 
exceeding 1500/mm3, lasting for longer than 6 months 
and being the cause of organ dysfunction or damage 
(3). For patients with chronic hypereosinophilia and 
skin involvement without any other organ dysfunc-
tion, the diagnosis of hypereosinophilic dermatitis was 
proposed (4). In 2001, the World Health Organization 
formulated the criteria that distinguished idiopathic 
HES from chronic eosinophilic leukemia and T-cell-me-
diated hypereosinophilia (5). The main criteria were the 
absence of increased percentage of blasts and the lack 
of clonality of eosinophils or lymphocytes.  
In the light of recent molecular studies that might 
have had implications for the management of eosin-
ophilic disorders, there was a need to create a new 
classification of these diseases. The Hypereosinophil-
ic Syndromes Working Group reached a consensus in 
2005 and divided the heterogeneous group of chron-
ic eosinophil-mediated disorders into six subgroups 
(6). This classification considers the possibility of clon-
ality of eosinophils, especially the presence of fusion 
of two genes on 4q12 (FIP1L1 and PDGFRA). 
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We present a case of a female Caucasian patient 
with chronic peripheral blood eosinophilia and un-
usual skin manifestations that did not suit the criteria 
of current classifications.
CASE REPoRt
Case history and clinical manifestations. A 
39-year old female patient has been in care of our 
department for three years now. When she was 20, 
she noticed mild palmoplantar hyperkeratosis. The 
symptoms did not progress and did not bother the 
patient. More serious problems appeared about four 
years ago. Palmoplantar hyperkeratosis worsened 
and started to itch. A couple of months later, pruritus 
became generalized and multiple papules appeared 
all over the body, especially on the wrists, neck, chest, 
lumbosacral region and lower legs. Some lesions 
were weeping. At that time, lichen planus was diag-
nosed and the patient was treated with prednisone 
and acitretin without any clinical effect. Then she was 
referred to our department.
In the next years, the disease progressed. Gener-
alized lymphadenopathy appeared. Other relevant 
symptoms were peripheral blood hypereosinophilia 
(up to 50%) and an increased level of total IgE. Two 
years ago, the patient started to have symptoms of 
chronic urticaria. 
The skin lesions evolved. Apart from palmoplan-
tar keratoderma, excessive pachydermia appeared on 
her hands and feet. The skin was markedly thickened, 
stiff and yellowish. Fingers and toes were stubby and 
skin markings became very deep (Fig. 1). Multiple hy-
perkeratotic and hyperpigmented papules, plaques 
and nodules were present on her elbows, knees, 
armpit areas, wrists and lower legs. Excessive pachy-
dermia and leukoplakia appeared also in the genital 
region, especially vulva. White hyperkeratosis was 
observed on oral mucous membranes, in the angles 
of the mouth.
In the course of the disease, the patient noticed 
greater susceptibility to different kinds of infections: 
recurrent vulval candidiasis, recurrent otitis media, as 
well as pneumonia.
Laboratory findings. The patient showed per-
sistent peripheral blood hypereosinophilia that 
ranged between 30% and 50%. Absolute eosino-
philia amounted to 2000-4000/mm3. Total IgE level 
was markedly and persistently elevated up to 13000 
IU/mL. The level of β-microglobulin was increased to 
2.86 mg/L (normal range: 0.7-1.8 mg/L). Bone mar-
row biopsy revealed excess of eosinophils at various 
stages with a predominance of mature forms. The di-
rect immunofluorescence test of skin lesions showed 
sparse granular deposits of C1q at the dermoepider-
mal junction. 
The following investigations were performed and 
were within the normal ranges: blood cell count, basic 
serum biochemistry, serum lactate dehydrogenase, 
levels of immunoglobulin subtypes, protein electro-
phoresis, serum level of vitamin B12, serologic tests 
for human immunodeficiency virus, patch tests and 
prick tests with basic allergens, x-rays of the chest, 
hands and head, electrocardiograms and echocar-
diograms, abdominal sonography, spirometry, karyo-
gram, and immunophenotyping of lymphocytes. The 
clonality of eosinophils was not demonstrated in the 
test for FIP1L1-PDGFRA fusion. Repeat stool examina-
tion for parasites was negative.
Histopathologic findings. Three skin biopsies 
were obtained: two were taken from the skin lesions 
and one from vulva. Sections were stained with he-
matoxylin and eosin. In addition, immunohistochem-
istry was performed on paraffin embedded section 
for T cells (CD3, CD43, CD45RO), B cells (CD20), mac-
rophages (CD68, MAC-387), Langerhans cells (CD1a, 
S-100 protein, langerine) and dermal dendrocytes 
(factor XIIIA-related antigen). Skin biopsies showed 
hyperkeratotic and acanthotic changes of the epi-
dermis. There was no spongiosis. All biopsies showed 
polymorphous infiltrates with lymphocytes, neutro-
phils, plasma cells and a large eosinophilic compo-
nent (predominantly perivascular). In some areas of 
the specimens, the infiltrate was focal and perivascu-
lar, whereas in others it was more diffuse and intersti-
tial (Fig.2). All biopsies showed small vessel prolifera-
tion and ectasia. Vessel thrombosis was not seen and 
flame figures were absent. The stains for mucins and 
Figure 1. Severe pachydermia of hands with keratoderma. 
The skin is thickened, yellowish, with deep skin markings 
and maceration. Fingers are very stubby. Multiple hyper-
keratotic papules are seen around the wrist.
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amyloid deposits were negative. In vulval biopsies, 
interstitial and perivascular infiltrates showed an im-
portant number of plasma cells. In addition, in vulval 
biopsies fibrosis was particularly marked.
Immunohistochemistry demonstrated the pres-
ence of T cells, whereas B cells were absent. There 
were a moderate number of dermal macrophages 
and a small number of dermal dendrocytes and der-
mal Langerhans cells. 
Additional findings. Serologic tests for toxoca-
riasis did not exclude the possibility of active disease 
and the patient underwent appropriate therapy. How-
ever, this treatment was not relevant for the course of 
hypereosinophilia and skin changes.
In the course of the disease, the patient under-
went thorough endocrinological diagnosis, mainly 
due to the suspected acromegaly. There was a tran-
sient increase in the plasma prolactin level, which 
was treated with bromocriptine. According to the en-
docrinologists’ opinion, this symptom had a reactive 
character and was not relevant for the clinical picture. 
Pituitary gland dysfunction including acromegaly 
was excluded. Magnetic resonance of the head was 
normal. There were no other hormonal disturbances.
tREAtMEnt AnD FoLLow UP
The patient was treated with acitretin, cyclospo-
rine A, oral prednisolone, methylprednisolone in 
intramuscular depot injections and antihistaminics 
with partial, transient or no clinical effect. The disease 
progressed in spite of treatment. Then we diagnosed 
pachydermatous eosinophilic dermatitis and the 
patient was administered combined therapy with 
dapsone 100 mg daily, oral methylprednisolone 24 
mg daily and fexofenadine 180 mg twice daily. After 
one month of treatment, the skin changes markedly 
improved with diminution of pruritus and flattening 
of skin lesions. The pachydermic changes were not as 
severe as before the triple treatment (Fig 3). The clini-
cal improvement was accompanied by normalization 
of eosinophilia. The serum level of total IgE was still 
elevated but the values were lower than at the begin-
ning of the disease. 
Four months after the introduction of combined 
treatment, we observed further improvement of skin 
lesions. However, we had to stop further dapsone ther-
apy because of skin changes of erythrodermic type 
that might have been caused by dapsone. At present, 
the patient is still on methylprednisolone-fexofenadine 
therapy and remains in the care of our department. 
DISCUSSIon
Disorders with hypereosinophilia are a heteroge-
neous group of diseases. First step in the diagnosis 
is excluding the reactive causes of high eosinophil 
level, such as parasitic infections, atopy or other aller-
gic disorders and malignancies (7,8). The current clas-
sification of nonreactive hypereosinophilic disorders 
divide these conditions into subgroups, taking into 
consideration different presentations and pathogen-
ic variants (5,8). The classification concerns fulfilling 
the diagnostic criteria of HES:
- FIP1L1-PDGFRA-positive HES, which is more ap-
propriately classified as FIP1L1-PDGFRA-positive 
chronic eosinophilic leukemia;
- chronic eosinophilic leukemia with clonality of eo-
sinophils or increased percentage of blasts;
- lymphocytic-mediated HES with chronic poly-
clonal hypereosinophilia secondary to IL-5 over-
production by T cells;
Figure 3. Improvement after therapy; the pachydermic 
changes are visibly diminished. 
Figure 2. Hyperkeratosis and acanthosis of the epidermis. 
Mixed diffused infiltrates, more dense in the perivascular 
whereas. (HE; x 400)
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- myeloproliferative HES with features suggesting 
the possibility of underlying myeloproliferative 
disorder (hepatomegaly, splenomegaly, anemia, 
increased serum level of vitamin B12, bone mar-
row hypercellularity with left shift in maturation); 
- idiopathic HES of unknown pathogenesis; and
- organ-restricted eosinophilic disease in which 
there is eosinophilic infiltration and damage of 
specific organ, e.g., eosinophilic pneumonia, eo-
sinophilic dermatitis, eosinophilic fasciitis.
The patient described in this paper does not ful-
fill any of the above-mentioned criteria. There was 
no evidence for parasitic or allergic disease. The epi-
sodes of chronic urticaria appeared in the course of 
the disease, probably secondary to persistent hypere-
osinophilia. The diagnosis of HES was taken in consid-
eration, mainly due to the degree of peripheral blood 
eosinophilia. However, thorough diagnostic work-up, 
biochemical and imaging, did not reveal any organ 
dysfunction or damage. Systemic changes are one 
of the symptoms of HES (7-9). One of other possible 
diagnoses could be eosinophilic dermatitis, a hypere-
osinophilia with only skin involvement. However, the 
skin symptoms described in this condition differed 
from the skin manifestations observed in our patient 
(4,10-12). Erythemas, maculae, pruritic papules and 
urticarial changes are usually present. There are no 
reports describing hypertrophy, pachydermic chang-
es or genital involvement.
We diagnosed pachydermatous eosinophilic der-
matitis in the patient presented. This condition was 
first described in 1996 by Jacyk et al. (13). The authors 
presented three cases of South African black teen-
age girls with pruritic papules and nodules on thick-
ened and pachydermatous skin with coexistence of 
lymphadenopathy. All patients had very similar clini-
cal appearance. The lesions were particularly exten-
sive on the extremities and in the genital region. The 
hands and fingers were stubby and stiff. There were 
no systemic changes. All patients showed persistent 
peripheral eosinophilia, leukocytosis and elevated 
serum IgE level. Bone marrow biopsies revealed an 
excess of mature eosinophils with no increase in blast 
cells. Other disturbances included increased IgG, IgA 
and IgM levels, elevated levels of circulating immune 
complexes and raised activity of serum lactate dehy-
drogenase, which were not present in our patient. 
Histologic picture showed similar findings as in biop-
sies taken from our patient: perivascular and/or diffuse 
infiltrates consisting mainly of mononuclear cells and 
eosinophils, small vessel proliferation and ectasia, 
and fibrosis in the dermis. Two patients described by 
Jacyk et al. (13) benefited from dapsone therapy, ad-
ministered in a dose of 100 mg/day. The third patient 
developed the signs of hemolysis, so the dose of dap-
sone was diminished to up to 50 mg/day and addition-
ally prednisolone 20 mg/day and cetirizine 10 mg/day 
were introduced. This therapy resulted in significant 
improvement. Being inspired by the good clinical ef-
fects of combined therapy with dapsone, steroids and 
antihistaminics, we also tried triple treatment in our 
patient. This treatment brought significant improve-
ment of the skin changes and decrease of itch. 
To the best of our knowledge, there are no other 
reports of similar conditions, suggesting that this may 
be an extremely rare disorder.
Several other conditions might be taken in con-
sideration on differential diagnosis in our patient. A 
similar clinical picture may be present in the course of 
T-cell lymphoma. Moraillon et al. describe a case of a 
male patient with papulonodular changes and pachy-
dermia with peripheral eosinophilia and elevated IgE 
level (14). More detailed examination allowed them 
to diagnose a T-cell pleomorphic lymphoma. Some-
times peripheral eosinophilia is present in patients 
with benign clonal T-cell population that produce 
high levels of IL-5 (15,16). Our patient did not pres-
ent clonality of circulating lymphocytes. The clonal 
type of hypereosinophilia was also ruled out by the 
negative test for FIP1L1-PDGFRA fusion. This kind of 
abnormality may have implications for the treatment 
and is an indication for imatinib therapy (7,8,17).
Other conditions considered on differential diagno-
sis included hyperimmunoglobulin E syndrome, Kimu-
ra’s disease, angiolymphoid hyperplasia with eosino-
philia (ALHE) and conditions with distal pachydermia or 
hyperkeratosis such as acropachyderma, Bureau-Bar-
riére-Thomas syndrome or palmoplantar keratodermas. 
However, the clinical picture of these disorders differed 
from the features observed in our patient (18-21).
ConCLUSIon
We would like to emphasize that the case present-
ed in this paper is the first example of this rare condi-
tion in a Caucasian patient and the first case reported 
in Europe. 
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